文献速递甲状腺疾病

仑伐替尼治疗放射性碘难治性分化型甲状腺癌的疗效与局限性:真实世界经验

Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
PubMed 文献 · Thyroid · 2020-01-23

单中心回顾性分析42例放射性碘难治性分化型甲状腺癌患者,仑伐替尼最佳总体疗效为部分缓解26例(62%)、疾病稳定10例(24%)、疾病进展6例(14%),3年总生存率51.0%、无进展生存率32.4%;23例(55%)患者背景不符合SELECT试验入选标准,17例(41%)进展后自行决定继续治疗,其3年总生存率43.0%、进展后生存期13.3个月(95%CI 6.1-未达到);作者认为真实世界中仑伐替尼疗效与SELECT试验相当。

要点

  • 42例RR-DTC患者中部分缓解26例(62%)、疾病稳定10例(24%)、疾病进展6例(14%)。
  • 3年总生存率51.0%,3年无进展生存率32.4%。
  • 23例(55%)患者背景不符合SELECT试验入选标准,17例(41%)进展后自行决定继续治疗。

核心结论

  • 真实世界研究显示RR-DTC患者背景特征广泛,进展后是否继续治疗取决于患者一般状况,本管理方案获得良好进展后生存,仑伐替尼疗效与SELECT试验相当,在真实世界中有效。

研究设计与样本

  • 单中心回顾性分析,纳入42例放射性碘难治性分化型甲状腺癌(RR-DTC)患者,评估仑伐替尼疗效。

主要发现

  • 最佳总体疗效:部分缓解26例(62%),疾病稳定10例(24%),疾病进展6例(14%)。
  • 3年总生存率51.0%,3年无进展生存率32.4%。
  • 23例(55%)患者背景不符合SELECT试验入选标准。
  • 疾病进展后17例(41%)患者自行决定继续仑伐替尼治疗,其3年总生存率43.0%,进展后生存期13.3个月(95%CI 6.1-未达到)。

临床怎么用

  • 作者认为真实世界中仑伐替尼对RR-DTC患者有效。
  • 作者指出进展后是否继续治疗基于患者一般状况由患者自行决定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The ultimate clinical goal of advanced cancer treatment is improvement of survival. Tyrosine kinase inhibitors (TKIs) were recently approved for radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) that is resistant to conventional therapies since they have significant potential to improve survival in patients who previously had no more treatment strategies available. However, eligible patients are limited in clinical practice, making it difficult to accurately determine the efficacy of TKIs. Patients and Methods: We retrospectively analyzed the efficacy of lenvatinib at a single institution, enrolling 42 RR-DTC patients. Results: The best overall response was partial remission in 26 (62%) patients, stable disease in 10 (24%) patients, and progressive disease (PD) in 6 (14%) patients. The results indicated three-year overall survival (OS) and progression-free survival rates of 51.0% and 32.4%, respectively. Twenty-three (55%) patients had backgrounds that did not match the inclusion criteria of the Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial. Furthermore, PD-experienced patients individually decided whether to continue lenvatinib, and 17 (41%) made the decision themselves; these patients had a three-year OS of 43.0% and postprogression survival (PPS) of 13.3 [95% confidence interval 6.1-not reached] months. Conclusions: Our real-world investigation revealed that patients have wide-ranging background characteristics, and the decision regarding continuation of therapy after PD is based on the patient's general condition. Our management protocol resulted in good PPS. Furthermore, our results indicated equivalent efficacy of lenvatinib as in the SELECT trial. In conclusion, lenvatinib proved effective for RR-DTC patients in a real-world setting.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Masaki C, Sugino K, Saito N, et al. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences. Thyroid. 2020. PMID: 31854270. doi:10.1089/thy.2019.0221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。